{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:21:03Z","timestamp":1788315663821,"version":"build-2803163510"},"reference-count":13,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2020,1,19]],"date-time":"2020-01-19T00:00:00Z","timestamp":1579392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,9]]},"abstract":"\n Background<\/jats:title>\n Evidence for the use of short-term daily parenteral parecoxib for refractory or uncontrolled non-surgical cancer pain is limited. This study aimed to characterise the real-world off-label use and report on clinical experiences in an Australian cancer cohort.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Eligible patients received at least one dose of parecoxib of an intended three-day course between October 2015 and December 2018. Data were collected to characterise the parecoxib treatment cohort (cancer diagnosis, metastases, sites and types of pain and prior analgesia). Parecoxib-related adverse events, pain scores (worst and median), and concurrent opioid use were assessed at 24\u2009h pre (T0) and 24 (T1), 48 (T2), 72 (T3) and 96 h (T4) post first parecoxib dose.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Sixty-five patients (39 males and 26 females) and 68 courses of parecoxib (three patients treated twice) were included in analyses: metastatic disease (86%), bone pain (54%) and taking \u22653 classes of analgesic medications (69%). Pain types varied (46% non-specific, 22% neuropathic and 32% other). Most (94%) received parecoxib by subcutaneous administration. Following parecoxib, median 24-h pain scores and worst pain scores improved for 59% (40\/68) and 50% (34\/68) of patients, respectively. In the first 24\u2009h (T0 to T1), median (4 vs. 2, p\u2009<\u20090.01) and worst (6 vs. 5, p\u2009<\u20090.01) pain scores were reduced and sustained to T4 (4 vs. 2.5, p\u2009=\u20090.01). Breakthrough analgesia requirements reduced for 63% (43\/68) of patients, while total concurrent opioid use remained constant. Mean\/median oral morphine equivalence for T0 vs. T1 was 111\u2009mg\/75\u2009mg vs. 162\u2009mg\/90\u2009mg, (p\u2009>\u20090.8). Two patients ceased parecoxib due to renal\/liver function abnormalities and two experienced mild injection-site reactions.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In this real-world study, parecoxib was utilised as adjunctive therapy in a select patient cohort to contribute to reduced pain scores with no new safety signals. Prospective randomised studies in larger cohorts would improve understanding of the effects of parecoxib.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/1078155219897744","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:34:32Z","timestamp":1579480472000},"page":"1407-1414","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Parecoxib as an adjunct therapy for the treatment of refractory non-surgical cancer pain"],"prefix":"10.1177","volume":"26","author":[{"given":"Arti","family":"Thakerar","sequence":"first","affiliation":[{"name":"Pharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seamus","family":"Dines-Muntaner","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences, Queensland University of Technology, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tijana","family":"Trifunovich","sequence":"additional","affiliation":[{"name":"Faculty Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5782-7912","authenticated-orcid":false,"given":"Marliese","family":"Alexander","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Peter MacCallum Cancer Centre, Melbourne, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Fullerton","sequence":"additional","affiliation":[{"name":"Parkville Integrated Palliative Care Service, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,1,19]]},"reference":[{"key":"bibr1-1078155219897744","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2014.0249"},{"key":"bibr2-1078155219897744","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161080-00010"},{"key":"bibr3-1078155219897744","doi-asserted-by":"crossref","unstructured":"Lloyd R, Derry S, Moore RA, et\u00a0al. Intravenous or intramuscular parecoxib for acute postoperative pain in adults.\n Cochrane Database Syst Rev\n 2009; 15: CD004771. DOI: 10.1002\/14651858.CD004771.pub4.","DOI":"10.1002\/14651858.CD004771.pub3"},{"key":"bibr4-1078155219897744","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.05.006"},{"key":"bibr5-1078155219897744","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2017-001348"},{"key":"bibr6-1078155219897744","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP-07-18-4629"},{"key":"bibr7-1078155219897744","unstructured":"Watson M, Armstrong P, Gannon C, et\u00a0al.\n Palliative care network guidelines plus\n , 2019, https:\/\/book.pallcare.info\/ (accessed 1 January 2019)."},{"key":"bibr8-1078155219897744","unstructured":"Moulds R. Therapeutic guidelines: palliative care. In: Allardice J (ed.)\n eTG complete\n . Melbourne: Therapeutic Guidelines Limited, 2019."},{"key":"bibr9-1078155219897744","unstructured":"Portenoy RK, Mehta Z, Ahmed E.\n Cancer pain management with opioids: optimizing analgesia\n . Waltham: UpToDate, 2019."},{"key":"bibr10-1078155219897744","doi-asserted-by":"publisher","DOI":"10.1097\/00002820-199704000-00002"},{"key":"bibr11-1078155219897744","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.31_suppl.217"},{"key":"bibr12-1078155219897744","unstructured":"Eastern Metropolitan Region Palliative Care Consortiu. Opioid conversion ratios guide to palliative care practice 2016, https:\/\/www.emrpcc.org.au\/uploads\/135\/Opioid-Conversions-May-2016.pdf (2016, accessed 20 December 2018)."},{"key":"bibr13-1078155219897744","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S136052"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219897744","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219897744","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219897744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:20Z","timestamp":1777688540000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219897744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,19]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1177\/1078155219897744"],"URL":"https:\/\/doi.org\/10.1177\/1078155219897744","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,19]]}}}